ArticleBMC psychiatry2025
Protein biomarkers for bipolar II disorder are correlated with affective cognitive performance.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Roles of PCSK9 in Alzheimer's Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn our previous research, we identified five candidate proteins-Carbonic Anhydrase 1 (CA-1), Matrix Metallopeptidase 9 (MMP9), Peroxiredoxin 2 (PRDX2), Phenylalanyl-tRNA Synthetase Subunit Beta (FARSB), and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-as prospective biomarkers for bipolar II disorder (BD-II). In this study, we explored the relationships between these potential plasma proteins and cognitive performance in BD-II patients using the Brief Assessment of Cognition in Affective Disorders (BACA), a validated tool for assessing cognitive deficits in mood disorders.
methodsOne hundred and seventeen participants with BD-II and 41 controls participated in this study. Plasma concentrations of the aforementioned proteins were measured, and cognitive performance was evaluated using the BACA.
resultsOur findings indicated that the BD-II group scored significantly lower than the control group across several BACA subtests, including Digit Sequencing, Symbol Coding, Verbal Memory, and Verbal Fluency, and in overall composite scores and all subtests of the Affective Interference Test (AIT) and Emotion Inhibition Test (EIT). Notably, we observed significant correlations in the BD-II group between levels of CA-1 (r = -0.26, P = 0.005), FARSB (r = 0.399, P < 0.001), and MMP9 (r = 0.24, P = 0.008) with the AIT-Cued affective words subtest. In contrast, a significant correlation was found between the Symbol Coding task and PCSK9 levels (r = 0.35, P = 0.003) in the control group, but not in the BD-II group.
conclusionThese findings offer new perspectives on the underlying mechanisms contributing to cognitive decline in individuals with BD-II.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.